{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:17:36Z","timestamp":1788787056992,"version":"build-2803163510"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"DOI":"10.1007\/s10620-026-10231-1","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:07:24Z","timestamp":1788782844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IBD Nurse-Led Clinical Pathways to Optimize Patient Safety in Advanced Therapies: A Narrative Review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-5354","authenticated-orcid":false,"given":"Daniele","family":"Napolitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Privitera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Radice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Schiavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Lorenzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Murgiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Parello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bezzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucrezia","family":"Laterza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loris Riccardo","family":"Lopetuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"10231_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","volume":"642","author":"L Hracs","year":"2025","unstructured":"Hracs L, Windsor JW, Gorospe J, Cummings M, Coward S, Buie MJ et al. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025;642:458\u2013466.","journal-title":"Nature."},{"key":"10231_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","volume":"18","author":"GG Kaplan","year":"2021","unstructured":"Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"10231_CR3","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u20132778.","journal-title":"Lancet."},{"key":"10231_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12876-023-03109-3","volume":"24","author":"Z Gu","year":"2024","unstructured":"Gu Z, Gu J, Liu P. The effectiveness of continuity of care in patients with inflammatory bowel disease: a systematic review. BMC Gastroenterol. 2024;24:24.","journal-title":"BMC Gastroenterol."},{"key":"10231_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/ecco-jcc\/jjy020","volume":"12","author":"K Kemp","year":"2018","unstructured":"Kemp K, Dibley L, Chauhan U, Greveson K, J\u00e4ghult S, Ashton K et al. Second N-ECCO Consensus Statements on the European Nursing Roles in Caring for Patients with Crohn\u2019s Disease or Ulcerative Colitis. J Crohns Colitis. 2018;12:760\u2013776.","journal-title":"J Crohns Colitis."},{"key":"10231_CR6","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/ecco-jcc\/jjaa023","volume":"14","author":"G Fiorino","year":"2020","unstructured":"Fiorino G, Lytras T, Younge L, Fidalgo C, Coenen S, Chaparro M et al. Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn\u2019s and Colitis Organisation [ECCO] Position Paper. J Crohns Colitis. 2020;14:1037\u20131048.","journal-title":"J Crohns Colitis."},{"key":"10231_CR7","first-page":"00288","volume":"S1590\u20138658","author":"G Fiorino","year":"2025","unstructured":"Fiorino G, Caprioli FA, Onali S, Macaluso FS, Bezzio C, Armelao F et al. Adaptation of the European Crohn\u2019s Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus. Dig Liver Dis. 2025;S1590\u20138658:00288\u201300289.","journal-title":"Dig Liver Dis."},{"key":"10231_CR8","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","volume":"120","author":"GR Lichtenstein","year":"2025","unstructured":"Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL et al. ACG Clinical Guideline: Management of Crohn\u2019s Disease in Adults. Am J Gastroenterol. 2025;120:1225\u20131264.","journal-title":"Am J Gastroenterol."},{"key":"10231_CR9","first-page":"401","volume":"38","author":"E Schiavoni","year":"2025","unstructured":"Schiavoni E, Greco D, Scaldaferri F, Napolitano D. Exploring the competencies of inflammatory bowel disease nurses in Italy: a cross-sectional survey. Ann Gastroenterol. 2025;38:401\u2013408.","journal-title":"Ann Gastroenterol."},{"key":"10231_CR10","doi-asserted-by":"publisher","first-page":"jjag054","DOI":"10.1093\/ecco-jcc\/jjag054","volume":"20","author":"S J\u00e4ghult","year":"2026","unstructured":"J\u00e4ghult S, Adamina M, Farrell D, Bager P, Czuber-Dochan W, Kemp K et al. Third N-ECCO Consensus Statements on the Nursing Roles in Caring for Patients with Inflammatory Bowel Disease. J Crohn\u2019s Colitis. 2026;20:jjag054.","journal-title":"J Crohn\u2019s Colitis."},{"key":"10231_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-036929","volume":"10","author":"C Martinez-Vinson","year":"2020","unstructured":"Martinez-Vinson C, Le S, Blachier A, Lipari M, Hugot J-P, Viala J. Effects of introduction of an inflammatory bowel disease nurse position on healthcare use. BMJ Open. 2020;10:e036929.","journal-title":"BMJ Open."},{"key":"10231_CR12","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/00365521.2018.1541477","volume":"53","author":"P Molander","year":"2018","unstructured":"Molander P, Jussila A, Toivonen T, M\u00e4kkeli P, Alho A, Kolho K-L. The impacts of an inflammatory bowel disease nurse specialist on the quality of care and costs in Finland. Scand J Gastroenterol. 2018;53:1463\u20131468.","journal-title":"Scand J Gastroenterol."},{"key":"10231_CR13","first-page":"213","volume":"73","author":"D Napolitano","year":"2020","unstructured":"Napolitano D, Martella P, Schiavoni E, Turchini L, Amatucci V, Armuzzi A et al. The awareness of the IBD nurse position among patients from an Italian tertiary IBD centre. Prof Inferm. 2020;73:213\u2013218.","journal-title":"Prof Inferm."},{"key":"10231_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12664-023-01500-2","volume":"43","author":"D Napolitano","year":"2024","unstructured":"Napolitano D, Settanni CR, Parisio L, Orgiana N, Poscia A, Schiavoni E et al. Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients. Indian J Gastroenterol. 2024;43:215\u2013225.","journal-title":"Indian J Gastroenterol."},{"key":"10231_CR15","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.cgh.2018.04.007","volume":"16","author":"M Regueiro","year":"2018","unstructured":"Regueiro M, Click B, Anderson A, Shrank W, Kogan J, McAnallen S et al. Reduced Unplanned Care and Disease Activity and Increased Quality of Life After Patient Enrollment in an Inflammatory Bowel Disease Medical Home. Clin Gastroenterol Hepatol. 2018;16:1777\u20131785.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10231_CR16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/ibd\/izad145","volume":"30","author":"N Yu","year":"2024","unstructured":"Yu N, Wu K, Samyue T, Fry S, Stanley A, Ross A et al. Outcomes of a Comprehensive Specialist Inflammatory Bowel Disease Nursing Service. Inflamm Bowel Dis. 2024;30:960\u2013969.","journal-title":"Inflamm Bowel Dis."},{"key":"10231_CR17","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/00365521.2017.1401116","volume":"53","author":"P Bager","year":"2018","unstructured":"Bager P, Chauhan U, Greveson K, J\u00e4ghult S, Moortgat L, Kemp K. Systematic review: advice lines for patients with inflammatory bowel disease. Scand J Gastroenterol. 2018;53:506\u2013512.","journal-title":"Scand J Gastroenterol."},{"key":"10231_CR18","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0140-6736(17)31327-2","volume":"390","author":"MJ de Jong","year":"2017","unstructured":"de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390:959\u2013968.","journal-title":"Lancet."},{"key":"10231_CR19","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.15403\/jgld-4627","volume":"31","author":"D Napolitano","year":"2022","unstructured":"Napolitano D, Schiavoni E, Scaldaferri F. Nurse Practitioners in Inflammatory Bowel Disease: The Emerging Role of the IBD Care Manager. J Gastrointestin Liver Dis. 2022;31:4627.","journal-title":"J Gastrointestin Liver Dis."},{"key":"10231_CR20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1186\/s12913-025-13323-2","volume":"25","author":"M Park","year":"2025","unstructured":"Park M, Lee J, Cheon JH, Yoon N, Yu J, Nam H. User-needs based app for patients with inflammatory bowel disease: development and usability study. BMC Health Serv Res. 2025;25:1285.","journal-title":"BMC Health Serv Res."},{"issue":"4","key":"10231_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1179\/2047480615Z.000000000329","volume":"24","author":"R Ferrari","year":"2015","unstructured":"Ferrari R. Writing narrative style literature reviews. Med Writ. 2015;24(4):230\u2013235.","journal-title":"Med Writ."},{"key":"10231_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","volume":"26","author":"MJ Grant","year":"2009","unstructured":"Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26:91\u2013108.","journal-title":"Health Info Libr J."},{"key":"10231_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0899-3467(07)60142-6","volume":"5","author":"BN Green","year":"2006","unstructured":"Green BN, Johnson CD, Adams A. Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med. 2006;5:101\u2013117.","journal-title":"J Chiropr Med."},{"key":"10231_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1136\/flgastro-2016-100696","volume":"7","author":"NS Taylor","year":"2016","unstructured":"Taylor NS, Bettey M, Wright J, Underhill C, Kerr S, Perry K et al. The impact of an inflammatory bowel disease nurse-led biologics service. Frontline Gastroenterol. 2016;7:283\u2013288.","journal-title":"Frontline Gastroenterol."},{"key":"10231_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/nursrep11020023","volume":"11","author":"C Rosso","year":"2021","unstructured":"Rosso C, Aaron AA, Armandi A, Caviglia GP, Vernero M, Saracco GM et al. Inflammatory Bowel Disease Nurse\u2014Practical Messages. Nurs Rep. 2021;11:229\u2013241.","journal-title":"Nurs Rep."},{"key":"10231_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","volume":"22","author":"S Vieujean","year":"2025","unstructured":"Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, Magro F et al. Understanding the therapeutic toolkit for inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2025;22:371\u2013394.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"10231_CR27","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","volume":"74","author":"GW Moran","year":"2025","unstructured":"Moran GW, Gordon M, Sinopolou V, Radford SJ, Darie A-M, Vuyyuru SK et al. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut. 2025;74:s1-101.","journal-title":"Gut."},{"key":"10231_CR28","doi-asserted-by":"publisher","first-page":"jjaf106","DOI":"10.1093\/ecco-jcc\/jjaf106","volume":"19","author":"T Kucharzik","year":"2025","unstructured":"Kucharzik T, Taylor S, Allocca M, Burisch J, Ellul P, Iacucci M et al. ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1. J. Crohn\u2019s and Colitis. 2025;19:jjaf106.","journal-title":"J. Crohn\u2019s and Colitis."},{"key":"10231_CR29","doi-asserted-by":"publisher","first-page":"jjag071","DOI":"10.1093\/ecco-jcc\/jjag071","volume":"20","author":"H Yanai","year":"2026","unstructured":"Yanai H, Ellul P, Verstockt B, Greuter T, Kopylov U, Casanova MJ et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J. Crohn\u2019s and Colitis. 2026;20:jjag071.","journal-title":"J. Crohn\u2019s and Colitis."},{"key":"10231_CR30","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/ecco-jcc\/jjw129","volume":"10","author":"Y Abitbol","year":"2016","unstructured":"Abitbol Y, Laharie D, Cosnes J, Allez M, Nancey S, Amiot A et al. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort. J Crohns Colitis. 2016;10:1179\u20131185.","journal-title":"J Crohns Colitis."},{"key":"10231_CR31","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1007\/s12664-024-01617-y","volume":"43","author":"R Banerjee","year":"2024","unstructured":"Banerjee R, Pal P, Hilmi I, Raghunathan N, Rahman M, Limsrivillai J et al. Primary caregiver burden and undiagnosed mental health illness in out-patients with inflammatory bowel disease-A multicentric prospective survey from the IBD Emerging Nations\u2019 Consortium. Indian J Gastroenterol. 2024;43:1156\u20131167.","journal-title":"Indian J Gastroenterol."},{"key":"10231_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/apt.16952","volume":"56","author":"SR Fehily","year":"2022","unstructured":"Fehily SR, Al-Ani AH, Abdelmalak J, Rentch C, Zhang E, Denholm JT et al. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther. 2022;56:6\u201327.","journal-title":"Aliment Pharmacol Ther."},{"key":"10231_CR33","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.3390\/jcm11133915","volume":"11","author":"S Riestra","year":"2022","unstructured":"Riestra S, Taxonera C, Zabana Y, Carpio D, Chaparro M, Barrio J et al. Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU. J Clin Med. 2022;11:3915.","journal-title":"J Clin Med."},{"key":"10231_CR34","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/MPG.0000000000003197","volume":"73","author":"RE Harris","year":"2021","unstructured":"Harris RE, Hegde V, Curtis L, Garrick V, Gervais L, Armstrong L et al. Epstein-Barr Virus Status and Subsequent Thiopurine Exposure Within a Paediatric Inflammatory Bowel Disease Population. J pediatr gastroenterol nutr. 2021;73:358\u2013362.","journal-title":"J pediatr gastroenterol nutr."},{"key":"10231_CR35","doi-asserted-by":"publisher","first-page":"1001055","DOI":"10.3389\/fimmu.2022.1001055","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, Zhao S, Cao Z. Impact of Epstein-Barr virus infection in patients with inflammatory bowel disease. Front Immunol. 2022;13:1001055.","journal-title":"Front Immunol."},{"key":"10231_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","volume":"15","author":"PF Van Rheenen","year":"2021","unstructured":"Van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL et al. The Medical Management of Paediatric Crohn\u2019s Disease: an ECCO-ESPGHAN Guideline Update. J Crohn\u2019s and Colitis. 2021;15:171\u2013194.","journal-title":"J Crohn\u2019s and Colitis."},{"key":"10231_CR37","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-106.","journal-title":"Gut."},{"key":"10231_CR38","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C et al. ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment. J Crohn\u2019s and Colitis. 2024;18:1531\u20131555.","journal-title":"J Crohn\u2019s and Colitis."},{"key":"10231_CR39","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s10620-023-07905-5","volume":"68","author":"M Almasry","year":"2023","unstructured":"Almasry M, Caldera F. Taking a JAB at How Gastroenterologists Can Increase Vaccination Rates in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2023;68:2787\u20132789.","journal-title":"Dig Dis Sci."},{"key":"10231_CR40","first-page":"247","volume":"32","author":"M Farshidpour","year":"2019","unstructured":"Farshidpour M, Charabaty A, Mattar MC. Improving immunization strategies in patients with inflammatory bowel disease. Ann Gastroenterol. 2019;32:247\u2013256.","journal-title":"Ann Gastroenterol."},{"key":"10231_CR41","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.dld.2021.05.015","volume":"53","author":"FS Macaluso","year":"2021","unstructured":"Macaluso FS, Liguori G, Galli M. Vaccinations in patients with inflammatory bowel disease. Dig Liver Dis. 2021;53:1539\u20131545.","journal-title":"Dig Liver Dis."},{"key":"10231_CR42","first-page":"5542","volume":"25","author":"D Napolitano","year":"2021","unstructured":"Napolitano D, Privitera G, Schiavoni E, Turchini L, Amatucci V, Pugliese D et al. The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19. Eur Rev Med Pharmacol Sci. 2021;25:5542\u20135546.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"10231_CR43","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s10620-023-07903-7","volume":"68","author":"J Patel","year":"2023","unstructured":"Patel J, Noureldin M, Fakhouri D, Farraye FA, Kovar-Gough I, Warren B et al. Interventions Increase Vaccination Rates in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2023;68:2921\u20132935.","journal-title":"Dig Dis Sci."},{"key":"10231_CR44","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3390\/vaccines13090961","volume":"13","author":"R Venuto","year":"2025","unstructured":"Venuto R, Rizzo CE, Lo Giudice D, Fries W, Ceccio C, Fedele F et al. Vaccination Coverage in Adult Patients with Inflammatory Bowel Disease: Impact of a Tailored Vaccination Pathway Including COVID-19 and Herpes Zoster in a University Hospital Vaccination Center. Vaccines (Basel). 2025;13:961.","journal-title":"Vaccines (Basel)."},{"key":"10231_CR45","first-page":"21","volume":"9","author":"NE Walsham","year":"2016","unstructured":"Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016;9:21\u201329.","journal-title":"Clin Exp Gastroenterol."},{"key":"10231_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2025-7-3","volume":"14","author":"AJ Kuriakose Kuzhiyanjal","year":"2025","unstructured":"Kuriakose Kuzhiyanjal AJ, Sethi-Arora K, Nigam GB, Limdi JK. Sphingosine-1-phosphate receptor modulators in ulcerative colitis \u2013 a narrative review of current evidence and practical considerations. DIC. 2025;14:1\u201319.","journal-title":"DIC."},{"key":"10231_CR47","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1517\/14740338.2011.583915","volume":"10","author":"CP Selinger","year":"2011","unstructured":"Selinger CP, Robinson A, Leong RW. Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease. Expert Opin Drug Saf. 2011;10:863\u2013870.","journal-title":"Expert Opin Drug Saf."},{"key":"10231_CR48","doi-asserted-by":"publisher","first-page":"jjae181","DOI":"10.1093\/ecco-jcc\/jjae181","volume":"19","author":"JK Limdi","year":"2025","unstructured":"Limdi JK, Rhodes S, Liu E, Kuriakose Kuzhiyanjal AJ, Brookes M, Farraye J et al. Knowledge, Values, and Preferences Regarding Contraceptive Choices Among Women Living With Inflammatory Bowel Disease. J Crohn\u2019s and Colitis. 2025;19:jjae181.","journal-title":"J Crohn\u2019s and Colitis."},{"key":"10231_CR49","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","volume":"24","author":"SR Knowles","year":"2018","unstructured":"Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I. Inflamm Bowel Dis. 2018;24:742\u2013751.","journal-title":"Inflamm Bowel Dis."},{"key":"10231_CR50","doi-asserted-by":"publisher","first-page":"452","DOI":"10.15403\/jgld-5084","volume":"32","author":"L Parisio","year":"2023","unstructured":"Parisio L, Settanni CR, Varca S, Laterza L, Lopetuso LR, Napolitano D et al. Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission. J Gastrointestin Liver Dis. 2023;32:452\u2013459.","journal-title":"J Gastrointestin Liver Dis."},{"key":"10231_CR51","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2019","unstructured":"Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13:144\u2013164.","journal-title":"J Crohns Colitis."},{"key":"10231_CR52","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/ecco-jcc\/jjz162","volume":"14","author":"MP Sparrow","year":"2020","unstructured":"Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S et al. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohns Colitis. 2020;14:542\u2013556.","journal-title":"J Crohns Colitis."},{"key":"10231_CR53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14712598.2024.2309300","volume":"24","author":"A Tursi","year":"2024","unstructured":"Tursi A, Mocci G, Scaldaferri F, Napolitano D, Maresca R, Pugliese D et al. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study. Expert Opin Biol Ther. 2024;24:101\u2013109.","journal-title":"Expert Opin Biol Ther."},{"key":"10231_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/NAN.0000000000000532","volume":"47","author":"B Nickel","year":"2024","unstructured":"Nickel B, Gorski L, Kleidon T, Kyes A, DeVries M, Keogh S et al. Infusion Therapy Standards of Practice. J Infus Nurs. 2024;47:1\u2013285.","journal-title":"J Infus Nurs."},{"key":"10231_CR55","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/ecco-jcc\/jjy150","volume":"13","author":"A Armuzzi","year":"2019","unstructured":"Armuzzi A, Avedano L, Greveson K, Kang T. Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies. J Crohns Colitis. 2019;13:259\u2013266.","journal-title":"J Crohns Colitis."},{"key":"10231_CR56","first-page":"492","volume":"29","author":"A Guarini","year":"2016","unstructured":"Guarini A, Marinis FD, Kohn A, Orzes N, D\u2019Inc\u00e0 R, Iannone T et al. Inflammatory bowel disease nurse specialists for patients on biological therapies: a nationwide Italian survey. Ann Gastroenterol. 2016;29:492\u2013496.","journal-title":"Ann Gastroenterol."},{"key":"10231_CR57","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489\u2013526.","journal-title":"J Gastroenterol."},{"key":"10231_CR58","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/ibd\/izad120","volume":"30","author":"S Bhat","year":"2024","unstructured":"Bhat S, Click B, Regueiro M. Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies. Inflamm Bowel Dis. 2024;30:829\u2013843.","journal-title":"Inflamm Bowel Dis."},{"key":"10231_CR59","unstructured":"Bayliss A, Currie L, McIntosh T, Ltd B. Infusion therapy standards: Rapid evidence review. 2016."},{"key":"10231_CR60","doi-asserted-by":"publisher","unstructured":"Moureau NL, editor. Vessel Health and Preservation: The Right Approach for Vascular Access. Cham: Springer International Publishing; 2019. https:\/\/doi.org\/10.1007\/978-3-030-03149-7","DOI":"10.1007\/978-3-030-03149-7"},{"key":"10231_CR61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/NAN.0000000000000460","volume":"45","author":"R Omkar Prasad","year":"2022","unstructured":"Omkar Prasad R, Chew T, Giri JR, Hoerauf K. Patient Experience With Vascular Access Management Informs Satisfaction With Overall Hospitalization Experience. J Infus Nurs. 2022;45:95\u2013103.","journal-title":"J Infus Nurs."},{"key":"10231_CR62","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.gastrohep.2021.04.011","volume":"45","author":"L Ramos","year":"2022","unstructured":"Ramos L, Ramos-Rodr\u00edguez J, Barreda RDL, Guti\u00e9rrez-Nicol\u00e1s F, Carrillo-Palau M, Alonso-Abreu I et al. Adherence to subcutaneous biologic treatment for inflammatory bowel disease. Gastroenterol Hepatol. 2022;45:335\u2013341.","journal-title":"Gastroenterol Hepatol."},{"key":"10231_CR63","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1093\/ibd\/izae015","volume":"30","author":"G Fiorino","year":"2024","unstructured":"Fiorino G, Bent-Ennakhil N, Varriale P, Braegger F, Hoefkens E. Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment. Inflamm Bowel Dis. 2024;30:2380\u20132394.","journal-title":"Inflamm Bowel Dis."},{"key":"10231_CR64","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2217\/imt-2021-0011","volume":"13","author":"JC Nieto","year":"2021","unstructured":"Nieto JC, Arajol C, Carmona L, Marras C, Cea-Calvo L. Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. Immunotherapy. 2021;13:433\u2013458.","journal-title":"Immunotherapy."},{"key":"10231_CR65","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40744-019-0144-8","volume":"6","author":"S Fenwick","year":"2019","unstructured":"Fenwick S, Thakur K, Munro D. Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey. Rheumatol Ther. 2019;6:195\u2013206.","journal-title":"Rheumatol Ther."},{"key":"10231_CR66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12919-021-00230-7","volume":"15","author":"L Jonaitis","year":"2021","unstructured":"Jonaitis L, Markovi\u0107 S, Farkas K, Gheorghe L, Krznari\u0107 \u017d, Salupere R et al. Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert\u2019s and patient\u2019s perspective. BMC Proc. 2021;15:25.","journal-title":"BMC Proc."},{"key":"10231_CR67","unstructured":"Entyvio | European Medicines Agency (EMA) [Internet]. 2018 [cited 2026 Aug 27]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/entyvio"},{"key":"10231_CR68","unstructured":"Remicade | European Medicines Agency (EMA) [Internet]. 2018 [cited 2026 Aug 27]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remicade"},{"key":"10231_CR69","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/ecco-jcc\/jjae093","volume":"18","author":"S Delen","year":"2024","unstructured":"Delen S, Jaghult S, Blumenstein I, Pouillon L, Bossuyt P. Framework of IBD Care Delivery Across Ages. J Crohns Colitis. 2024;18:55\u201366.","journal-title":"J Crohns Colitis."},{"key":"10231_CR70","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.pec.2021.10.017","volume":"105","author":"S Gohil","year":"2022","unstructured":"Gohil S, Majd Z, Sheneman JC, Abughosh SM. Interventions to improve medication adherence in inflammatory bowel disease: A systematic review. Patient Education and Counseling. 2022;105:1731\u20131742.","journal-title":"Patient Education and Counseling."},{"key":"10231_CR71","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/medicina60020250","volume":"60","author":"K Dutt","year":"2024","unstructured":"Dutt K, Vasudevan A. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. Medicina (Kaunas). 2024;60:250.","journal-title":"Medicina (Kaunas)."},{"key":"10231_CR72","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2024-000998","volume":"3","author":"D Zeraatkar","year":"2024","unstructured":"Zeraatkar D, Pitre TS, Kirsh S, Jassal T, Ling M, Hussain M et al. Proactive therapeutic drug monitoring of biologic drugs in patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis: systematic review and meta-analysis. BMJ Med. 2024;3:e000998.","journal-title":"BMJ Med."},{"key":"10231_CR73","doi-asserted-by":"publisher","first-page":"jjaf173","DOI":"10.1093\/ecco-jcc\/jjaf173","volume":"20","author":"P Hilley","year":"2025","unstructured":"Hilley P, Chin S, Wong D, De Cruz P. Implementation of Values based healthcare in inflammatory bowel disease-a review article. J Crohns Colitis. 2025;20:jjaf173.","journal-title":"J Crohns Colitis."},{"key":"10231_CR74","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/healthcare12121210","volume":"12","author":"C Mercuri","year":"2024","unstructured":"Mercuri C, Catone M, Bosco V, Guillari A, Rea T, Doldo P et al. Motivational Interviewing as a Strategy to Improve Adherence in IBD Treatment: An Integrative Review Amidst COVID-19 Disruptions. Healthcare. 2024;12:1210.","journal-title":"Healthcare."},{"key":"10231_CR75","doi-asserted-by":"publisher","first-page":"6252049","DOI":"10.1155\/jonm\/6252049","volume":"2025","author":"S Ruksakulpiwat","year":"2025","unstructured":"Ruksakulpiwat S, Pongsuwun K, Junphongsri P, Preeprem C, Nguantad S, Samart B. Nurse-Led Interventions to Improve Health, Adherence, and Functional Outcomes in Adults and Older Adults With Multimorbidity: A Systematic Review of Randomized and Quasiexperimental Studies. Journal of Nursing Management. 2025;2025:6252049.","journal-title":"Journal of Nursing Management."},{"key":"10231_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.580803","volume":"7","author":"F Liu","year":"2020","unstructured":"Liu F, Lee SA, Riordan SM, Zhang L, Zhu L. Global Studies of Using Fecal Biomarkers in Predicting Relapse in Inflammatory Bowel Disease. Front Med (Lausanne). 2020;7:580803.","journal-title":"Front Med (Lausanne)."},{"key":"10231_CR77","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3390\/jcm12031206","volume":"12","author":"J-T Shi","year":"2023","unstructured":"Shi J-T, Chen N, Xu J, Goyal H, Wu Z-Q, Zhang J-X et al. Diagnostic Accuracy of Fecal Calprotectin for Predicting Relapse in Inflammatory Bowel Disease: A Meta-Analysis. J Clin Med. 2023;12:1206.","journal-title":"J Clin Med."},{"key":"10231_CR78","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u20132128.","journal-title":"Lancet."},{"key":"10231_CR79","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","volume":"20","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C et al. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn\u2019s Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022;20:578-590.e4.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10231_CR80","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","volume":"17","author":"H Gordon","year":"2023","unstructured":"Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Al Sulais E et al. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. Journal of Crohn\u2019s and Colitis. 2023;17:827\u2013854.","journal-title":"Journal of Crohn\u2019s and Colitis."},{"key":"10231_CR81","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1097\/MIB.0000000000000685","volume":"22","author":"JKJ Gaidos","year":"2016","unstructured":"Gaidos JKJ, Bickston SJ. How to Optimize Colon Cancer Surveillance in Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2016;22:1219\u20131230.","journal-title":"Inflamm Bowel Dis."},{"key":"10231_CR82","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.3390\/diagnostics15192457","volume":"15","author":"S Lavalle","year":"2025","unstructured":"Lavalle S, Vitello A, Masiello E, Dell\u2019Anna G, Romeo P, Montana A et al. The Role of Imaging in Inflammatory Bowel Diseases: From Diagnosis to Individualized Therapy. Diagnostics. 2025;15:2457.","journal-title":"Diagnostics."},{"key":"10231_CR83","doi-asserted-by":"publisher","first-page":"E16","DOI":"10.1097\/SGA.0000000000000436","volume":"43","author":"D Simian","year":"2020","unstructured":"Simian D, Flores L, Quera R, Ib\u00e1\u00f1ez P, Figueroa C, Lubascher J et al. The Role of an Inflammatory Bowel Disease Nurse in the Follow-Up of Patients From a Latin American Inflammatory Bowel Disease Program. Gastroenterology Nursing. 2020;43:E16-23.","journal-title":"Gastroenterology Nursing."},{"key":"10231_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2025.102056","author":"P Puca","year":"2025","unstructured":"Puca P, Coppola G, Parello S, Capobianco I, Colantuono S, Scaldaferri F et al. Atherosclerotic cardiovascular disease and inflammatory bowel disease: epidemiology, pathogenesis and risk assessment. Best Pract Res Clin Gastroenterol. 2025. https:\/\/doi.org\/10.1016\/j.bpg.2025.102056.","journal-title":"Best Pract Res Clin Gastroenterol."},{"key":"10231_CR85","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017;376:1723\u20131736.","journal-title":"N Engl J Med."},{"key":"10231_CR86","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1093\/ecco-jcc\/jjad075","volume":"17","author":"AJ Kuriakose Kuzhiyanjal","year":"2023","unstructured":"Kuriakose Kuzhiyanjal AJ, Nigam GB, Antoniou GA, Farraye FA, Cross RK, Limdi JK. Management of Inflammatory Bowel Disease Using E-health Technologies: A Systematic Review and Meta-Analysis. J Crohn\u2019s and Colitis. 2023;17:1596\u20131613.","journal-title":"J Crohn\u2019s and Colitis."},{"key":"10231_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014821.pub2","author":"M Gordon","year":"2023","unstructured":"Gordon M, Sinopoulou V, Lakunina S, Gjuladin-Hellon T, Bracewell K, Akobeng AK. Remote care through telehealth for people with inflammatory bowel disease. Cochrane Database Systematic Rev. 2023. https:\/\/doi.org\/10.1002\/14651858.CD014821.pub2.","journal-title":"Cochrane Database Systematic Rev."},{"key":"10231_CR88","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11894-020-0751-0","volume":"22","author":"LA George","year":"2020","unstructured":"George LA, Cross RK. Remote Monitoring and Telemedicine in IBD: Are We There Yet? Curr Gastroenterol Rep. 2020;22:12.","journal-title":"Curr Gastroenterol Rep."},{"key":"10231_CR89","first-page":"7277","volume":"26","author":"F Bossa","year":"2022","unstructured":"Bossa F, Valvano MR, Vetrone LM, Guerra M, Lopetuso LR, Carparelli S et al. Evaluation of factors associated with trust in telemedicine in patients with inflammatory bowel disease during COVID-19 pandemic: a multicenter cross-sectional survey. Eur Rev Med Pharmacol Sci. 2022;26:7277\u20137284.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"10231_CR90","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/medicina62010147","volume":"62","author":"P Martella","year":"2026","unstructured":"Martella P, Lo Cascio A, Povoli A, Molino L, Cangelosi G, Orgiana N et al. Determinants of Telemedicine Satisfaction in Inflammatory Bowel Disease Patients: A Multi-Centre Cross-Sectional Study. Medicina. 2026;62:147.","journal-title":"Medicina."},{"key":"10231_CR91","doi-asserted-by":"publisher","first-page":"1635290","DOI":"10.3389\/fmed.2025.1635290","volume":"12","author":"S Li","year":"2025","unstructured":"Li S, Ni Z, Ma Y, Chen Y, Sun H, Jin J. Pioneering the IBD specialist nurse role in China: a shared decision-making model for clinical practice innovation. Front Med. 2025;12:1635290. https:\/\/doi.org\/10.3389\/fmed.2025.1635290.","journal-title":"Front Med."},{"key":"10231_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e25357","volume":"10","author":"K Wang","year":"2024","unstructured":"Wang K, Zhu Y, Liu K, Zhu H, Ouyang M. Adverse events of biologic or small molecule therapies in clinical trials for inflammatory bowel disease: A systematic review and meta-analysis. Heliyon. 2024;10:e25357.","journal-title":"Heliyon."},{"key":"10231_CR93","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","volume":"98","author":"A Cheifetz","year":"2003","unstructured":"Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315\u20131324.","journal-title":"Am J Gastroenterol."},{"key":"10231_CR94","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3390\/pharmaceutics16091185","volume":"16","author":"A Di Rienzo","year":"2024","unstructured":"Di Rienzo A, Marinelli L, Dimmito MP, Toto EC, Di Stefano A, Cacciatore I. Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems. Pharmaceutics. 2024;16:1185.","journal-title":"Pharmaceutics."},{"key":"10231_CR95","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","volume":"9","author":"L Lichtenstein","year":"2015","unstructured":"Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM et al. Infliximab-Related Infusion Reactions: Systematic Review. ECCOJC. 2015;9:806\u2013815.","journal-title":"ECCOJC."},{"key":"10231_CR96","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","volume":"8","author":"FM Ruemmele","year":"2014","unstructured":"Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC et al. Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn\u2019s disease. Journal of Crohn\u2019s and Colitis. 2014;8:1179\u20131207.","journal-title":"Journal of Crohn\u2019s and Colitis."},{"key":"10231_CR97","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/MIB.0000000000001003","volume":"23","author":"JK Hou","year":"2017","unstructured":"Hou JK, Kramer JR, Richardson P, Sansgiry S, El-Serag HB. Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists. Inflamm Bowel Dis. 2017;23:254\u2013260.","journal-title":"Inflamm Bowel Dis."},{"key":"10231_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2022.104322","volume":"134","author":"CS Lee","year":"2022","unstructured":"Lee CS, Westland H, Faulkner KM, Iovino P, Thompson JH, Sexton J et al. The effectiveness of self-care interventions in chronic illness: A meta-analysis of randomized controlled trials. Int J Nurs Stud. 2022;134:104322.","journal-title":"Int J Nurs Stud."},{"key":"10231_CR99","first-page":"893","volume":"15","author":"Y-A Lee","year":"2025","unstructured":"Lee Y-A, Yen H-H, Chen Y-Y. Serological Assessment of Hepatitis in Patients with Inflammatory Bowel Disease in Taiwan: A Retrospective Cohort Analysis. Life (Basel). 2025;15:893.","journal-title":"Life (Basel)."},{"key":"10231_CR100","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s10620-018-5042-3","volume":"63","author":"R Shah","year":"2018","unstructured":"Shah R, Ho EY, Kramer JR, Richardson P, Sansgiry S, El-Serag HB et al. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists. Dig Dis Sci. 2018;63:1551\u20131557.","journal-title":"Dig Dis Sci."},{"key":"10231_CR101","doi-asserted-by":"publisher","first-page":"2455536","DOI":"10.1080\/07853890.2025.2455536","volume":"57","author":"H Yang","year":"2025","unstructured":"Yang H, An T, Zhao Y, Shi X, Wang B, Zhang Q. Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis. Ann Med. 2025;57:2455536.","journal-title":"Ann Med."},{"key":"10231_CR102","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.cgh.2025.04.031","volume":"24","author":"S Honap","year":"2026","unstructured":"Honap S, Temido MJ, Shakweh E, Badrulhisham F, Shields N, Mehta S et al. Janus Kinase Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study. Clin Gastroenterol Hepatol. 2026;24:484-492.e7.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10231_CR103","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","volume":"143","author":"MD Long","year":"2012","unstructured":"Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390-399.e1.","journal-title":"Gastroenterology."},{"key":"10231_CR104","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.crohns.2013.01.009","volume":"7","author":"G Mocci","year":"2013","unstructured":"Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013;7:769\u2013779.","journal-title":"J Crohns Colitis."},{"key":"10231_CR105","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3748\/wjg.v29.i10.1539","volume":"29","author":"E Cheah","year":"2023","unstructured":"Cheah E, Huang JG. Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies. World J Gastroenterol. 2023;29:1539\u20131550.","journal-title":"World J Gastroenterol."},{"key":"10231_CR106","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1053\/j.gastro.2023.10.033","volume":"166","author":"PS Dulai","year":"2024","unstructured":"Dulai PS, Singh S, Jairath V, Wong E, Narula N. Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases. Gastroenterology. 2024;166:396-408.e2.","journal-title":"Gastroenterology."},{"key":"10231_CR107","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3390\/ph16091272","volume":"16","author":"M Imbrizi","year":"2023","unstructured":"Imbrizi M, Magro F, Coy CSR. Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years. Pharmaceuticals (Basel). 2023;16:1272.","journal-title":"Pharmaceuticals (Basel)."},{"key":"10231_CR108","doi-asserted-by":"publisher","first-page":"444","DOI":"10.15403\/jgld-5128","volume":"32","author":"RB Mateescu","year":"2023","unstructured":"Mateescu RB, Gheorghe C, Trifan AV, Saftoiu A, Seicean A, Diculescu MM et al. Safety, Efficacy and Persistence of Advanced Therapies in Inflammatory Bowel Disease: Results from ORIGINS. A Retrospective Observational Study. J Gastrointestin Liver Dis. 2023;32:444\u2013451.","journal-title":"J Gastrointestin Liver Dis."},{"key":"10231_CR109","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/biomedicines13020305","volume":"13","author":"V Calvez","year":"2025","unstructured":"Calvez V, Puca P, Di Vincenzo F, Del Gaudio A, Bartocci B, Murgiano M et al. Novel Insights into the Pathogenesis of Inflammatory Bowel Diseases. Biomedicines. 2025;13:305.","journal-title":"Biomedicines."},{"key":"10231_CR110","doi-asserted-by":"publisher","first-page":"103329","DOI":"10.1016\/j.ebiom.2021.103329","volume":"66","author":"G Cui","year":"2021","unstructured":"Cui G, Fan Q, Li Z, Goll R, Florholmen J. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease Current and novel biomarkers. eBioMedicine. 2021;66:103329.","journal-title":"eBioMedicine."},{"key":"10231_CR111","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jcag\/gwad027","volume":"7","author":"S Meade","year":"2024","unstructured":"Meade S, Squirell E, Hoang TT, Chow J, Rosenfeld G. An Update on Anti-TNF Biosimilar Switching-Real-World Clinical Effectiveness and Safety. J Can Assoc Gastroenterol. 2024;7:30\u201345.","journal-title":"J Can Assoc Gastroenterol."},{"key":"10231_CR112","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/14712598.2023.2185510","volume":"23","author":"G Mocci","year":"2023","unstructured":"Mocci G, Tursi A, Maconi G, Cataletti G, Mantia B, Serio M et al. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn\u2019s disease: results from an Italian multicenter study. Expert Opin Biol Ther. 2023;23:293\u2013304.","journal-title":"Expert Opin Biol Ther."},{"key":"10231_CR113","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1403a179","volume":"14","author":"A Borghi","year":"2024","unstructured":"Borghi A, Odorici G, Bardazzi F, Filippi F, Bigi L, Lasagni C et al. Real Life Comparative Effectiveness of IL-23 Inhibitors in the Treatment of Moderate to Severe Psoriasis: A Multicenter Experience. Dermatol Pract Concept. 2024;14:e2024179.","journal-title":"Dermatol Pract Concept."},{"key":"10231_CR114","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.cgh.2024.04.016","volume":"22","author":"M Fumery","year":"2024","unstructured":"Fumery M, Caron B, H\u00e9buterne X, Altwegg R, Roblin X, Stefanescu C et al. Long-term Outcome of Risankizumab in Crohn\u2019s Disease: a Real-world GETAID Study. Clin Gastroenterol Hepatol. 2024;22:2451-2458.e1.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10231_CR115","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158:1554-1573.e12.","journal-title":"Gastroenterology."},{"key":"10231_CR116","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159\u20131171.","journal-title":"Lancet."},{"key":"10231_CR117","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1080\/14656566.2023.2230126","volume":"24","author":"A Tursi","year":"2023","unstructured":"Tursi A, Mocci G, Cingolani L, Savarino E, Pica R, Cocco A et al. Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study. Expert Opin Pharmacother. 2023;24:1649\u20131656.","journal-title":"Expert Opin Pharmacother."},{"key":"10231_CR118","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/ecco-jcc\/jjz187","volume":"14","author":"M Adamina","year":"2020","unstructured":"Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A et al. ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Surgical Treatment. J Crohns Colitis. 2020;14:155\u2013168.","journal-title":"J Crohns Colitis."},{"key":"10231_CR119","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S2468-1253(25)00129-3","volume":"10","author":"S Danese","year":"2025","unstructured":"Danese S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, Jairath V, D\u2019Haens G et al. Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2025;10:882\u2013895.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10231_CR120","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/S2468-1253(22)00233-3","volume":"7","author":"S Vermeire","year":"2022","unstructured":"Vermeire S, Sands BE, Tilg H, Tulassay Z, Kempinski R, Danese S et al. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. Lancet Gastroenterol Hepatol. 2022;7:1024\u20131035.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10231_CR121","doi-asserted-by":"publisher","first-page":"jjaf074","DOI":"10.1093\/ecco-jcc\/jjaf074","volume":"19","author":"S Vermeire","year":"2025","unstructured":"Vermeire S, Nitcheu J, Gineste P, Flatres A, Santo J, Scherrer D et al. Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study. J Crohns Colitis. 2025;19:jjaf074.","journal-title":"J Crohns Colitis."},{"key":"10231_CR122","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/ibd\/izad124","volume":"30","author":"N Tubau-Juni","year":"2024","unstructured":"Tubau-Juni N, Bassaganya-Riera J, Leber AJ, Alva SS, Hontecillas R. Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation. Inflamm Bowel Dis. 2024;30:103\u2013113.","journal-title":"Inflamm Bowel Dis."},{"key":"10231_CR123","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","volume":"156","author":"U Mahadevan","year":"2019","unstructured":"Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M et al. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019;156:1508\u20131524.","journal-title":"Gastroenterology."},{"key":"10231_CR124","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/gutjnl-2025-336402","volume":"75","author":"U Mahadevan","year":"2026","unstructured":"Mahadevan U, Seow CH, Barnes EL, Chaparro M, Flanagan E, Friedman S et al. Global consensus statement on the management of pregnancy in inflammatory bowel disease. Gut. 2026;75:208\u2013251.","journal-title":"Gut."},{"key":"10231_CR125","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","volume":"11","author":"P Gionchetti","year":"2017","unstructured":"Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn\u2019s Disease 2016: Part 2: Surgical Management and Special Situations. J Crohns Colitis. 2017;11:135\u2013149.","journal-title":"J Crohns Colitis."},{"key":"10231_CR126","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.14309\/ajg.0000000000002326","volume":"118","author":"AM Parian","year":"2023","unstructured":"Parian AM, Obi M, Fleshner P, Schwartz DA. Management of Perianal Crohn\u2019s Disease. Am J Gastroenterol. 2023;118:1323\u20131331.","journal-title":"Am J Gastroenterol."},{"key":"10231_CR127","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.3748\/wjg.v30.i44.4745","volume":"30","author":"JP Singh","year":"2024","unstructured":"Singh JP, Aleissa M, Drelichman ER, Mittal VK, Bhullar JS. Navigating the complexities of perianal Crohn\u2019s disease: Diagnostic strategies, treatment approaches, and future perspectives. World J Gastroenterol. 2024;30:4745\u20134753.","journal-title":"World J Gastroenterol."},{"key":"10231_CR128","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.14309\/ajg.0000000000003541","volume":"120","author":"FA Farraye","year":"2025","unstructured":"Farraye FA, Melmed GY, Lichtenstein GR, Barnes EL, Limketkai BN, Caldera F et al. ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2025;120:1447\u20131473.","journal-title":"Am J Gastroenterol."},{"key":"10231_CR129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262571","volume":"17","author":"J Park","year":"2022","unstructured":"Park J, Yoon H, Shin CM, Park YS, Kim N, Lee DH. Clinical factors to predict flare-up in patients with inflammatory bowel disease during international air travel: A prospective study. PLoS ONE. 2022;17:e0262571.","journal-title":"PLoS ONE."},{"key":"10231_CR130","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jpn3.70121","volume":"81","author":"AC Hauer","year":"2025","unstructured":"Hauer AC, Sultan M, Darma A, Altamimi E, Serban DE, Assa A et al. Management of pediatric inflammatory bowel diseases in limited-resource settings: A position paper from the Paediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2025;81:866\u2013898.","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"10231_CR131","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-058037","volume":"151","author":"M Bouhuys","year":"2023","unstructured":"Bouhuys M, Lexmond WS, Van Rheenen PF. Pediatric Inflammatory Bowel Disease. Pediatrics. 2023;151:e2022058037.","journal-title":"Pediatrics."},{"key":"10231_CR132","doi-asserted-by":"publisher","first-page":"ii31","DOI":"10.1093\/ecco-jcc\/jjae087","volume":"18","author":"SA Vuijk","year":"2024","unstructured":"Vuijk SA, Camman AE, De Ridder L. Considerations in Paediatric and Adolescent Inflammatory Bowel Disease. J Crohn\u2019s and Colitis. 2024;18:ii31-45.","journal-title":"J Crohn\u2019s and Colitis."},{"key":"10231_CR133","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-026-09883-w","author":"D Napolitano","year":"2026","unstructured":"Napolitano D, Bassola B, Lusignani M, Cilluffo S. The Role of Nurse-Patient Mutuality on Self-Care Behaviors in Adults Living with Inflammatory Bowel Disease: A Multicenter Cross-Sectional Study. Dig Dis Sci. 2026. https:\/\/doi.org\/10.1007\/s10620-026-09883-w.","journal-title":"Dig Dis Sci."},{"key":"10231_CR134","first-page":"006597","volume":"4","author":"R Belling","year":"2009","unstructured":"Belling R, McLaren S, Woods L. Specialist nursing interventions for inflammatory bowel disease. Cochrane Database Syst Rev. 2009;4:006597.","journal-title":"Cochrane Database Syst Rev."},{"key":"10231_CR135","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T et al. ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment. Journal of Crohn\u2019s and Colitis. 2020;14:4\u201322.","journal-title":"Journal of Crohn\u2019s and Colitis."},{"key":"10231_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinme.2025.100317","volume":"25","author":"M Colwill","year":"2025","unstructured":"Colwill M, Ward A, Jacob K, Hall R, Rasasingam D, O\u2019Neill S et al. Advanced therapy screening in inflammatory bowel disease and the impact of clinical nurse specialists: A retrospective analysis of electronic patient records. Clinical Medicine. 2025;25:100317.","journal-title":"Clinical Medicine."},{"key":"10231_CR137","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384\u2013413.","journal-title":"Am J Gastroenterol."},{"key":"10231_CR138","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160:1570\u20131583.","journal-title":"Gastroenterology."},{"key":"10231_CR139","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13012-015-0242-0","volume":"10","author":"P Nilsen","year":"2015","unstructured":"Nilsen P. Making sense of implementation theories, models and frameworks. Implement Sci. 2015;10:53.","journal-title":"Implement Sci."},{"key":"10231_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101382","volume":"46","author":"Y Chen","year":"2022","unstructured":"Chen Y, Shen J. Core indicators of an evaluation and guidance system for quality of care in inflammatory bowel disease centers: A critical review. EClinicalMedicine. 2022;46:101382.","journal-title":"EClinicalMedicine."},{"key":"10231_CR141","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1111\/jan.14744","volume":"77","author":"R Spagnuolo","year":"2021","unstructured":"Spagnuolo R, Corea A, Napolitano D, Nistic\u00f2 E, Pagnotta R, Pagliuso C et al. Nursing-sensitive outcomes in adult inflammatory bowel disease: A systematic review. J Adv Nurs. 2021;77:2248\u20132266.","journal-title":"J Adv Nurs."},{"key":"10231_CR142","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1186\/s12913-022-08985-1","volume":"22","author":"L Alvestad","year":"2022","unstructured":"Alvestad L, Jelsness-J\u00f8rgensen L-P, Goll R, Clancy A, Gressnes T, Valle PC et al. Health-related quality of life in inflammatory bowel disease: a comparison of patients receiving nurse-led versus conventional follow-up care. BMC Health Serv Res. 2022;22:1602.","journal-title":"BMC Health Serv Res."},{"key":"10231_CR143","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/apt.17926","volume":"59","author":"B Bokemeyer","year":"2024","unstructured":"Bokemeyer B, Plachta-Danielzik S, Steiner IM, Pohlschneider D, Urzica E, Hartmann P et al. Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBDBIO-ASSIST study). Aliment Pharmacol Ther. 2024;59:1082\u20131095.","journal-title":"Aliment Pharmacol Ther."},{"key":"10231_CR144","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/MEG.0000000000000839","volume":"29","author":"S Coenen","year":"2017","unstructured":"Coenen S, Weyts E, Vermeire S, Ferrante M, Noman M, Ballet V et al. Effects of introduction of an inflammatory bowel disease nurse position on the quality of delivered care. Eur J Gastroenterol Hepatol. 2017;29:646\u2013650.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10231_CR145","doi-asserted-by":"publisher","first-page":"otaf063","DOI":"10.1093\/crocol\/otaf063","volume":"7","author":"D Napolitano","year":"2025","unstructured":"Napolitano D, Scaldaferri F, Leone S, Previtali E, Fiorino G, Caprioli F et al. The Dedicated Inflammatory Bowel Disease Nurse, If You Know Them, You Love Them: Survey of the Italian IBD Patients\u2019 Association. Crohn\u2019s Colitis 360. 2025;7:otaf063.","journal-title":"Crohn\u2019s Colitis 360."},{"key":"10231_CR146","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izag018","author":"D Napolitano","year":"2026","unstructured":"Napolitano D, Bozzetti M, Vanzi V, Lo Cascio A, Capobianco I, Gasbarrini A et al. Bowel urgency in inflammatory bowel disease: A concept analysis. Inflamm Bowel Dis. 2026. https:\/\/doi.org\/10.1093\/ibd\/izag018.","journal-title":"Inflamm Bowel Dis."},{"key":"10231_CR147","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.3390\/jcm14082562","volume":"14","author":"D Napolitano","year":"2025","unstructured":"Napolitano D, Lo Cascio A, Bozzetti M, Povoli A, Grubissa S, Molino L et al. Patient Satisfaction with IBD Undergoing Colonoscopy: A Multicenter Cross-Sectional Study. J Clin Med. 2025;14:2562.","journal-title":"J Clin Med."},{"key":"10231_CR148","first-page":"353","volume":"11","author":"L Dibley","year":"2017","unstructured":"Dibley L, Bager P, Czuber-Dochan W, Farrell D, Jelsness-J\u00f8rgensen L-P, Kemp K et al. Identification of Research Priorities for Inflammatory Bowel Disease Nursing in Europe: a Nurses-European Crohn\u2019s and Colitis Organisation Delphi Survey. J Crohns Colitis. 2017;11:353\u2013359.","journal-title":"J Crohns Colitis."},{"key":"10231_CR149","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-5985.25.03976-2","author":"D Napolitano","year":"2025","unstructured":"Napolitano D, Lo Cascio A, Bozzetti M, Guberti M. Implementing research, improving practice: synergizing the clinical research nurse and the nurse researcher. Minerva Gastroenterol. 2025. https:\/\/doi.org\/10.23736\/S2724-5985.25.03976-2.","journal-title":"Minerva Gastroenterol."},{"key":"10231_CR150","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70458","volume":"10","author":"D Napolitano","year":"2026","unstructured":"Napolitano D, Bozzetti M, Mora V, Pastore F, Caruso R, Guberti M et al. Nursing-Led Support Across the Standard Care-Clinical Trial-Standard Care Pathway in Inflammatory Bowel Disease: A Review With Realist-Informed Interpretation. JGH Open. 2026;10:e70458.","journal-title":"JGH Open."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10231-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10231-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10231-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:03:47Z","timestamp":1788786227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10231-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":150,"alternative-id":["10231"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10231-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is based on a narrative review of published literature and did not involve human participants or patient data.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}